Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Hannah Palko

Physician Assistant, Medical Pinehurst, NC Physician Assistant

NPI 1881101236 CMS profile 10608032

125 Fox Hollow Rd Ste 210, Pinehurst, NC 28374

Open in the dashboard

General payments

$20,572

826 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hannah Palko of Pinehurst, NC is reported in the CMS Open Payments database as having received $20,572 across 826 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,466 211
2024 General $4,586 193
2023 General $3,527 171
2022 General $3,371 167
2021 General $4,622 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hannah Palko
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Hannah Palko were reported at $4,466. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Hannah Palko Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $4,622 $156 $41–$563 $132
2022 $3,371 $185 $55–$649 $149
2023 $3,527 $199 $58–$717 $160
2024 $4,586 $206 $62–$740 $164
2025 $4,466 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $4,312 229 payments
  2. Sun Pharmaceutical Industries Inc. $4,259 56 payments
  3. Janssen Biotech, Inc. $1,804 67 payments
  4. Genzyme Corporation $1,731 52 payments
  5. Regeneron Healthcare Solutions, Inc. $1,303 48 payments
  6. E.R. Squibb & Sons, L.L.C. $1,303 63 payments
  7. UCB, Inc. $954 55 payments
  8. Novartis Pharmaceuticals Corporation $884 49 payments
  9. LEO Pharma Inc. $790 32 payments
  10. Lilly USA, LLC $755 49 payments
  11. Other $2,478 126 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,955 813 payments
  2. Honoraria $3,025 3 payments
  3. Education $485 9 payments
  4. Travel and Lodging $107 1 payment
Products named General payments · program years 2021–2025
  1. Winlevi $2,777 21 payments
  2. RINVOQ $2,538 130 payments
  3. DUPIXENT Immunology $2,347 70 payments
  4. TREMFYA $1,762 65 payments
  5. SKYRIZI $1,344 71 payments
  6. SOTYKTU $1,284 62 payments
  7. DUPIXENT Inflammation And Immunology $1,014 37 payments
  8. Absorica LD $933 15 payments
  9. ADBRY $707 28 payments
  10. Bimzelx $665 34 payments
  11. Other $7,354 415 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

965

Median for Physician Assistant: 241

Drug cost

$859,631

Median for Physician Assistant: $4,110

Branded share of claims

13.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 19 $398,159
Dupixent Pen Dupilumab Brand 66 $262,454
Humira(Cf) Pen Adalimumab Brand 12 $166,983
Clobetasol Propionate Generic 151 $9,884
Fluorouracil Generic 56 $4,749
Tretinoin Generic 48 $4,727
Triamcinolone Acetonide Generic 142 $2,166
Desonide Generic 33 $2,024
Metronidazole Generic 25 $1,419
Ketoconazole Generic 97 $1,313

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$118,820

Of which drugs: $33

Medicare patients

794

Average age 73

Services billed

4,125

452 women, 342 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 32%
Ischemic heart disease 26%
Chronic kidney disease 21%
Depression 18%
COPD 17%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 51 $26

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $733
$733 — —
DUPIXENT
  • GENZYME CORPORATION $420
  • Regeneron Healthcare Solutions, Inc. $289
$709 66 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $627
$627 — —
TREMFYA
  • Janssen Biotech, Inc. $581
$581 — —
Bimzelx
  • UCB, Inc. $275
$275 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

826 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record